Thesis

Cross-Reactivity Analysis between SARS-CoV-2 T Cell Epitopes with Epitopes from OPV, BCG, and MMR Vaccines Specific for Indonesian Population

---

Nearly all countries worldwide have been affected by the enormity of COVID-19 caused by
SARS-CoV-2, including Indonesia. This pandemic has a variation in symptoms and the number of
deaths among Indonesian COVID-19 patients, which could be explained by the nonspecific immunity
provided by the cross-reactive epitopes from LAVs (BCG, OPV, and MMR). However, there is still a
lack of base evidence showing the cross-reactivity between these LAVs and SARS-CoV-2 specific to
the Indonesian population. Through in silico approach, the SARS-CoV-2 Wuhan-Hu-1 isolate T cell
epitopes were predicted against HLA alleles specific to the Indonesian population. The generated
epitopes were then compared with the OPV, BCG, and MMR sequence to identify similar patterns.
The cross-reactive epitopes were further rechecked and inspected for their population coverage in
Indonesia. Both BCG and MMR contain 15 and 7 strong binding cross-reactive epitopes specific to the
Indonesian population, which have 2 to 4 amino acid substitutions compared with SARS-CoV-2
epitopes. Despite that, the cross-reactive epitopes are potentially able to induce either cross-reactive
CD8+ or CD4+ T cells against SARS-CoV-2. Additionally, most cross-reactive epitopes have similar or
higher population coverage than SARS-CoV-2 epitopes, ranging from 4.83% to 73.5%. In contrast, no
cross-reactive epitopes were found from OPV specific to the Indonesian population, which may be
due to the genome nature of poliovirus. Overall, these identified cross-reactive patterns may serve as
a pillar for uncovering the full potential of beneficial cross-protection against SARS-CoV-2 and future
pandemics.

---

Availability

Detail Information

Series Title

-

Call Number

BM 22-019

Publisher

i3L, Jakarta : i3L, Jakarta., 2022

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

SARS-COV-2
cross-reactivity
BCG
OPV,
MMR
immune response

Specific Detail Info

-

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment